XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/28/2025 08:00 PDT] XRTX Expected to Trade Up After Bullish Patterns Develop
• [04/22/2025 14:55 PDT] XORTX Therapeutics Inc (NASDAQ:XRTX), Up By 100% ($0.92) From $0.92 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/22/2025 14:55 PDT] XORTX Therapeutics Inc (NASDAQ:XRTX), Up By 100% ($0.9) From $0.9 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/16/2025 07:17 PDT] XRTX Expected to Trade Up After Bullish Patterns Develop
• [04/04/2025 11:45 PDT] XORTX Therapeutics Inc (NASDAQ:XRTX), Down By 100% ($0.99) From $0.99 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/04/2025 07:37 PDT] XRTX Expected to Trade Up After Bullish Patterns Develop
• [03/25/2025 07:08 PDT] XRTX Expected to Trade Down After Bearish Patterns Develop
• [03/10/2025 07:53 PDT] XRTX Expected to Trade Up After Bullish Patterns Develop